Consensus report

consensus report

Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II)   

17

1 3

20. Reiberger T, Ulbrich G, Ferlitsch A, Payer BA, Pinter M, 

Peck-Radosavljevic M. Carvedilol for prophylaxis of vari-

ceal bleeding in cirrhotic patients with hemodynamic 

non-response to propranolol. Hepatology. 2010;52 (Suppl 

1):A21.

21. Garcia-Pagan JC, Morillas R, Banares R, Albillos A, Villan-

ueva C, Vila C, Genesca J, et al. Propranolol plus placebo 

versus propranolol plus isosorbide-5-mononitrate in the 

prevention of a first variceal bleed: a double-blind RCT. 

Hepatology. 2003;37:1260–6.

22. Ben-Ari Z, Cardin F, McCormick AP, Wannamethee G, 

Burroughs AK. A predictive model for failure to control 

bleeding during acute variceal haemorrhage. J Hepatol. 

1999;31:443–50.

23. Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poy-

nard T. Antibiotic prophylaxis for the prevention of bac-

terial infections in cirrhotic patients with gastrointestinal 

bleeding: a meta-analysis. Hepatology. 1999;29:1655–61.

24. Moitinho E, Escorsell A, Bandi JC, Salmeron JM, Garcia-

Pagan JC, Rodes J, Bosch J. Prognostic value of early mea-

surements of portal pressure in acute variceal bleeding. 

Gastroenterology. 1999;117:626–31.

25. Hubmann R, Bodlaj G, Czompo M, Benko L, Pichler P, Al-

Kathib S, Kiblbock P, et al. The use of self-expanding metal 

stents to treat acute esophageal variceal bleeding. Endos-

copy. 2006;38:896–901.

26. Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L, Sierra 

A, Guevara C, Jimenez E, Marrero JM, et al. Influence of 

portal hypertension and its early decompression by TIPS 

placement on the outcome of variceal bleeding. Hepatol-

ogy. 2004;40:793–801.

27. Garcia-Pagan JC, Caca K, Bureau C, Laleman W, Appen-

rodt B, Luca A, Abraldes JG, et al. Early use of TIPS in 

patients with cirrhosis and variceal bleeding. N Engl J Med. 

2010;362:2370–9.

28. Bureau C, Peron JM, Alric L, Morales J, Sanchez J, Barange 

K, Payen JL, et al. “A La Carte” treatment of portal hyperten-

sion: adapting medical therapy to hemodynamic response 

for the prevention of bleeding. Hepatology. 2002;36:1361–6.

29. Primignani M, Carpinelli L, Preatoni P, Battaglia G, Carta 

A, Prada A, Cestari R, et al. Natural history of portal 

hypertensive gastropathy in patients with liver cirrhosis. 

The New Italian Endoscopic Club for the study and treat-

ment of esophageal varices (NIEC). Gastroenterology. 

2000;119:181–7.

30. Stewart CA, Sanyal AJ. Grading portal gastropathy: valida-

tion of a gastropathy scoring system. Am J Gastroenterol. 

2003;98:1758–65.

31. Ward EM, Raimondo M, Rosser BG, Wallace MB, Dickson 

RD. Prevalence and natural history of gastric antral vascu-

lar ectasia in patients undergoing orthotopic liver trans-

plantation. J Clin Gastroenterol. 2004;38:898–900.

32. Sarin SK, Lahoti D, Saxena SP, Murthy NS, Makwana UK. 

Prevalence, classification and natural history of gastric var-

ices: a long-term follow-up study in 568 portal hyperten-

sion patients. Hepatology. 1992;16:1343–9.

33. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention 

and management of gastroesophageal varices and variceal 

hemorrhage in cirrhosis. Hepatology. 2007;46:922–38.

34. Lo GH, Lai KH, Cheng JS, Chen MH, Chiang HT. A prospec-

tive, randomized trial of butyl cyanoacrylate injection ver-

sus band ligation in the management of bleeding gastric 

varices. Hepatology. 2001;33:1060–4.

35. Sarin SK, Jain AK, Jain M, Gupta R. A randomized con-

trolled trial of cyanoacrylate versus alcohol injection in 

patients with isolated fundic varices. Am J Gastroenterol. 

2002;97:1010–5.

36. Tan PC, Hou MC, Lin HC, Liu TT, Lee FY, Chang FY, Lee SD. 

A randomized trial of endoscopic treatment of acute gastric 

variceal hemorrhage: N-butyl-2-cyanoacrylate injection 

versus band ligation. Hepatology. 2006;43:690–7.

37. Kang EJ, Jeong SW, Jang JY, Cho JY, Lee SH, Kim HG, 

Kim SG, et al. Long-term result of endoscopic histoacryl 

(N-butyl-2-cyanoacrylate) injection for treatment of gastric 

varices. World J Gastroenterol. 2011;17:1494–1500.

38. Seewald S, Ang TL, Imazu H, Naga M, Omar S, Groth S, 

Seitz U, et al. A standardized injection technique and regi-

men ensures success and safety of N-butyl-2-cyanoacrylate 

injection for the treatment of gastric fundal varices (with 

videos). Gastrointest Endosc. 2008;68:447–54.

39. Akahoshi T, Hashizume M, Shimabukuro R, Tanoue K, 

Tomikawa M, Okita K, Gotoh N, et al. Long-term results 

of endoscopic histoacryl injection sclerotherapy for gas-

tric variceal bleeding: a 10-year experience. Surgery. 

2002;131:S176–81.

40. Kumamoto M, Toyonaga A, Inoue H, Miyakoda K, Morita Y, 

Emori K, Sakamoto Y, et al. Long-term results of balloon-

occluded retrograde transvenous obliteration for gastric 

fundal varices: hepatic deterioration links to portosystemic 

shunt syndrome. J Gastroenterol Hepatol. 2010;25:1129–35.

41. Hiraga N, Aikata H, Takaki S, Kodama H, Shirakawa H, 

Imamura M, Kawakami Y, et al. The long-term outcome 

of patients with bleeding gastric varices after balloon-

occluded retrograde transvenous obliteration. J Gastroen-

terol. 2007;42:663–72.

42. Arai H, Abe T, Takagi H, Mori M. Efficacy of balloon-

occluded retrograde transvenous obliteration, percutane-

ous transhepatic obliteration and combined techniques for 

the management of gastric fundal varices. World J Gastro-

enterol. 2006;12:3866–73.

43.  Chau TN, Patch D, Chan YW, Nagral A, Dick R, Burroughs AK. 

“Salvage” transjugular intrahepatic portosystemic shunts: 

gastric fundal compared with esophageal variceal bleeding 

(see comments). Gastroenterology. 1998;114:981–7.

44. Boyer TD, Haskal ZJ. The role of transjugular intrahepatic 

portosystemic shunt (TIPS) in the management of portal 

hypertension: update 2009. Hepatology. 2010;51:306.

45. Pache I, Bilodeau M. Severe haemorrhage following 

abdominal paracentesis for ascites in patients with liver 

disease. Aliment Pharmacol Ther. 2005;21:525–9.

46. Boyer TD, Zia P, Reynolds TB. Effect of indometha-

cin and prostaglandin A1 on renal function and plasma 

renin activity in alcoholic liver disease. Gastroenterology. 

1979;77:215–22.

47. Pariente EA, Bataille C, Bercoff E, Lebrec D. Acute effects 

of captopril on systemic and renal hemodynamics and on 

renal function in cirrhotic patients with ascites. Gastroen-

terology. 1985;88:1255–9.

48. Gentilini P, Romanelli RG, La Villa G, Maggiore Q, Pesci-

ullesi E, Cappelli G, Casini Raggi V, et al. Effects of low-

dose captopril on renal hemodynamics and function 

in patients with cirrhosis of the liver. Gastroenterology. 

1993;104:588–94.

49. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cir-

rhosis and ascites. N Engl J Med. 2004;350:1646–54.

50. EASL. EASL clinical practice guidelines on the manage-

ment of ascites, spontaneous bacterial peritonitis, and hep-

atorenal syndrome in cirrhosis. J Hepatol. 2010;53:397–417.

51. Rimola A, Garcia-Tsao G, Navasa M, Piddock LJ, Pla-

nas R, Bernard B, Inadomi JM. Diagnosis, treatment and 

prophylaxis of spontaneous bacterial peritonitis: a con-

sensus document. International Ascites Club. J Hepatol. 

2000;32:142–53.

---